A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

NCT07073079 · clinicaltrials.gov ↗
RECRUITING
Status
250
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie